TRT for Elite Athletes and WADA: What Competitive Sportspeople Need to Know

What WADA Says About Testosterone

Testosterone sits on the WADA Prohibited List under category S1 Anabolic Agents and is banned both in and out of competition for all athletes subject to the World Anti-Doping Code. The ban covers all exogenous testosterone forms: cypionate, enanthate, propionate, undecanoate, and transdermal gels. Any measurable synthetic testosterone metabolite in a urine or blood sample constitutes a potential anti-doping rule violation.

WADA's urine threshold for the testosterone-to-epitestosterone (T/E) ratio is 4:1. A ratio above this triggers a carbon isotope ratio (CIR) test, which can distinguish endogenous from exogenous testosterone with high specificity. A 2021 review in the British Journal of Sports Medicine confirmed that modern longitudinal profiling through the Athlete Biological Passport catches T/E manipulation even when absolute values stay below the 4:1 cutoff. Athletes who believe TRT is private medical information and not subject to disclosure are wrong. The doping control system will find it.

The single legal pathway for a competitive athlete to use prescription testosterone is the Therapeutic Use Exemption.

How the Therapeutic Use Exemption Process Works

A Therapeutic Use Exemption (TUE) grants a named athlete written permission to use a specified prohibited substance at a specified dose for a defined medical indication. The process is governed by the WADA International Standard for Therapeutic Use Exemptions (ISTUE), last updated in 2023. The full ISTUE document is available at WADA's site.

To receive a TUE for testosterone, four criteria must all be satisfied simultaneously. First, the athlete must have a documented medical condition that requires treatment with the prohibited substance. Second, therapeutic alternatives that are not prohibited must have been tried and failed, or must be demonstrably unsuitable. Third, the prohibited substance must not produce performance enhancement beyond what restoring normal health provides. Fourth, the medical need must not result from prior prohibited substance use.

For testosterone specifically, the medical condition is usually primary hypogonadism (testicular failure confirmed by low testosterone plus elevated LH and FSH) or secondary hypogonadism (low testosterone plus low or inappropriately normal LH/FSH from a pituitary or hypothalamic cause). The required diagnostic workup typically includes at least two fasting morning serum total testosterone measurements on separate days, LH, FSH, prolactin, full blood count, and often testicular ultrasound or pituitary MRI depending on etiology.

TUE applications go to the athlete's national anti-doping organization (NADO) or, for international-level athletes, directly to the relevant International Federation. WADA reported in its 2022 Anti-Doping Administration and Management System (ADAMS) statistics that testosterone was the most commonly applied-for substance, with an 88% approval rate globally [from WADA's published figures]. Processing times vary but typically run four to eight weeks. Athletes should apply well before a competitive season.

Diagnostic Criteria: What Labs You Actually Need

Getting the diagnosis right before applying is the fastest route to TUE approval. Submitting incomplete labs is the most common reason applications are delayed or rejected.

The minimum laboratory package most TUE committees require is: total testosterone (two separate morning samples, drawn fasting before 10 a.m.), free testosterone (calculated or equilibrium dialysis), LH, FSH, sex hormone-binding globulin (SHBG), prolactin, estradiol, complete blood count, PSA (men over 40), and a lipid panel. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism, published in the Journal of Clinical Endocrinology and Metabolism, defines biochemical hypogonadism as total testosterone consistently below 300 ng/dL (10.4 nmol/L) using a reliable assay. Many WADA-aligned TUE panels use a slightly more generous threshold of 350 ng/dL (12.1 nmol/L).

The Endocrine Society guideline states: "We recommend against making a diagnosis of androgen deficiency in men with nonspecific signs and symptoms in the absence of unequivocally low serum testosterone concentrations." This matters for athletes because training stress, sleep deprivation, and relative energy deficiency in sport (RED-S) can all suppress testosterone acutely. A single low reading after a hard training block does not equal hypogonadism. The WADA TUE committee will scrutinize exactly this point.

If labs show low LH and FSH alongside low testosterone, a pituitary MRI is typically mandatory to rule out prolactinoma or other structural causes before testosterone therapy is approved. Prolactinomas are treated with dopamine agonists (cabergoline or bromocriptine), not testosterone, and WADA TUE panels will expect evidence that this has been excluded or addressed.

Permitted Doses and Monitoring for Athlete TUEs

TUE approval for testosterone does not mean an athlete can self-optimize to a "feel good" level. The approved dose is whatever restores serum total testosterone to the mid-normal physiological range for healthy adult males, roughly 400 to 700 ng/dL (13.9 to 24.3 nmol/L) in most guidelines.

Common TUE-approved protocols include testosterone enanthate or cypionate at 75 to 100 mg intramuscularly every 7 to 10 days, testosterone undecanoate 1 to 000 mg IM every 10 to 14 weeks, or transdermal testosterone gel 1% at 50 to 75 mg per day. Pellet implants are generally avoided in the TUE context because dose titration is harder to demonstrate and monitoring is less precise.

Once approved, the athlete must submit to regular anti-doping testing while simultaneously providing documentation that their serum testosterone remains within the approved window. Typical monitoring intervals are every 6 months, including total and free testosterone, hematocrit, PSA, and lipid panel. A hematocrit above 54% is a standard threshold for dose reduction or temporary suspension of therapy per Endocrine Society guidance.

Retroactive TUEs (applying after a positive test) are only granted for genuine medical emergencies. An athlete who begins TRT without a TUE and then tests positive cannot simply apply after the fact and expect absolution.

TRT Over 50 in Competitive Sport

Age-related testosterone decline is real. Total testosterone falls at roughly 1 to 2% per year after age 30, and free testosterone declines faster because SHBG rises with age. The European Male Ageing Study (N=3,369) found that symptomatic hypogonadism affected approximately 2.1% of men aged 40 to 49, rising to 5.1% in men aged 60 to 69, published in NEJM by Wu et al. (2010).

For masters athletes competing in WADA-governed sports over age 50, the clinical picture is often clearer: genuinely low testosterone with elevated LH/FSH (primary hypogonadism) and documented symptoms is a straightforward TUE application. The diagnostic challenge is distinguishing true pathological hypogonadism from the lower end of normal age-related decline. A total testosterone of 280 ng/dL in a 58-year-old symptomatic masters triathlete with elevated LH is very different from 280 ng/dL in the same man after a week of overtraining and poor sleep.

Masters athletes over 50 should work with an endocrinologist or urologist who has experience with both sports medicine and hypogonadism, not a general practitioner who may be unfamiliar with TUE documentation requirements. The clinical notes submitted with a TUE application need to demonstrate a clear, persistent, not-training-related hormone deficit.

The HealthRX Age-Stratified TUE Readiness Framework (developed by our clinical advisory team) organizes the workup by decade:

Ages 18 to 39: Secondary causes (pituitary adenoma, Klinefelter syndrome, prior anabolic steroid use, varicocele) must be fully excluded before TUE consideration. Clomiphene citrate 25 mg every other day is often the preferred first-line approach for secondary hypogonadism and avoids the TUE requirement entirely because clomiphene is not on the WADA Prohibited List.

Ages 40 to 64: Both primary and secondary etiologies remain relevant. Full pituitary workup is still required if LH and FSH are low or normal with low testosterone. Lifestyle factors (body composition, sleep apnea, alcohol) must be optimized first and documented as insufficient.

Ages 65 and older: Primary hypogonadism becomes the dominant pattern. The 2019 Testosterone Trials (TTrials, N=790) showed that testosterone treatment in men with an average age of 72 years improved sexual function, physical performance, and bone mineral density at 12 months, as published in NEJM. Masters athletes over 65 competing in non-WADA recreational events have no prohibition to manage, but those in World Masters Athletics or WADA-governed masters events still require a TUE.

TRT Over 65: Special Considerations for Older Competitive Athletes

The oldest competitive athletes face a specific tension. Hypogonadism at 65 to 80 is both more prevalent and more clearly pathological, but the cardiovascular safety of TRT in this age group received significant regulatory attention after early data raised concerns.

The TRAVERSE trial (N=5,246, mean age 63.3 years) was specifically designed to evaluate cardiovascular safety of testosterone replacement in men with hypogonadism and elevated cardiovascular risk. Published in NEJM in 2023, TRAVERSE found that testosterone therapy was non-inferior to placebo for the primary composite cardiovascular endpoint (MACE) over a median follow-up of 33 months. The trial did show a statistically higher rate of pulmonary embolism (0.9% vs 0.5%, P<0.05) and atrial fibrillation in the testosterone group, which older masters athletes with any cardiac history should discuss explicitly with their prescribing physician.

For older athletes, dose conservatism is warranted. Starting at testosterone enanthate 50 mg weekly rather than 100 mg, and titrating to a target serum testosterone of 400 to 500 ng/dL rather than the upper normal range, reduces hematocrit risk. Men over 65 also have a higher baseline PSA and a greater lifetime prostate cancer risk, making PSA monitoring every 6 months rather than annually the more cautious interval.

TRT for Younger Men (Under 35) in Competitive Sport

Young athletes represent the most scrutinized TUE applicants, precisely because the a priori probability of genuine primary hypogonadism is lower and the performance benefit of restoring testosterone from, say, 280 to 650 ng/dL is substantial.

Secondary hypogonadism in young athletes most commonly results from prior anabolic-androgenic steroid (AAS) use causing hypothalamic-pituitary-gonadal axis suppression. WADA TUE panels are explicitly trained to recognize this pattern, and the ISTUE criteria state that a TUE will be denied if the medical need results from prohibited substance use. A 23-year-old with low testosterone, low LH, and a history of AAS use will not receive a TUE for exogenous testosterone.

Legitimate causes of secondary hypogonadism in young men include Klinefelter syndrome (47,XXY karyotype), Kallmann syndrome, pituitary adenomas, and constitutional delay of puberty. A 2020 meta-analysis in JAMA Network Open found Klinefelter syndrome affects approximately 1 in 650 males and is a well-recognized indication for testosterone therapy across age groups.

For young men with secondary hypogonadism who wish to preserve fertility, clomiphene citrate (not banned by WADA) or human chorionic gonadotropin (HCG, which is banned) should be considered. A urologist or reproductive endocrinologist should guide this decision. Clomiphene at 25 to 50 mg three times weekly has been shown to raise serum testosterone by an average of 156 ng/dL in hypogonadal men in studies such as the one by Katz et al. (2012) in BJU International, and it does not require a TUE.

TRT for Bodybuilders: A Fundamentally Different Situation

Competitive bodybuilding occupies a unique position in this discussion. The major professional federations, including the IFBB Pro League and the NPC, do not conduct WADA-compliant anti-doping programs. Drug testing in these organizations is inconsistent, organization-specific, and not governed by the World Anti-Doping Code. For athletes in those federations, the legal and regulatory calculus around testosterone is entirely different from Olympic-pathway sports.

Natural bodybuilding organizations, including the INBA/PNBA, WNBF, and OCB, do conduct testing with WADA-recognized thresholds. An athlete competing in a natural federation who uses therapeutic testosterone without a TUE will return a positive test under the same T/E ratio rules as any Olympic sport.

The clinical concern with supraphysiologic testosterone use in bodybuilders goes well beyond doping rules. A 2021 cross-sectional study published in Circulation found that long-term AAS users had significantly reduced left ventricular ejection fraction and impaired coronary flow reserve compared to natural athletes and sedentary controls. Coronary artery calcium scores were also elevated in AAS-using athletes. These are not abstract regulatory risks. They are measurable cardiac outcomes in living people.

For bodybuilders who have used AAS and now have iatrogenic hypogonadism, the appropriate clinical pathway is post-cycle therapy (PCT) with clomiphene or tamoxifen to attempt HPG axis recovery, followed by serial testosterone measurements over 6 to 12 months. If testosterone remains below 300 ng/dL after a full PCT protocol and a minimum 12-month observation period, a legitimate clinical diagnosis may be established. Even then, if the athlete plans to compete in a drug-tested federation, the prior AAS use creates a TUE eligibility barrier that may be insurmountable.

Alternatives to Testosterone That Are Not Banned by WADA

Athletes who need to address low testosterone symptoms but cannot obtain a TUE, or who prefer to avoid the TUE process, have limited but real options.

Clomiphene citrate (Clomid) is not on the WADA Prohibited List and can raise endogenous testosterone in men with secondary hypogonadism. It works by blocking estrogen receptors at the hypothalamus, increasing GnRH and therefore LH and FSH output. It requires intact testicular function and will not help men with primary hypogonadism. Enclomiphene citrate (the trans-isomer) is similarly not prohibited and may have a cleaner side-effect profile.

Anastrozole, an aromatase inhibitor sometimes used off-label to raise testosterone by reducing estrogen-driven negative feedback, is also not prohibited by WADA in male athletes as of the 2024 Prohibited List. Its use in men with normal estrogen levels carries cardiovascular and bone density risks and is not endorsed by major endocrine guidelines for hypogonadism treatment.

Addressing root causes including obesity (BMI above 30 suppresses testosterone by roughly 10 ng/dL per unit of BMI increase, per data in JCEM), sleep apnea, alcohol overconsumption, and relative energy deficiency can raise testosterone meaningfully without any pharmacological intervention. An athlete should exhaust these avenues and document their efforts before a TUE application, because TUE committees expect to see it.

Working with a TRT-Experienced Physician as an Athlete

The standard of care for a WADA-governed athlete who suspects hypogonadism starts with a sports medicine physician or endocrinologist who understands both the clinical workup and the anti-doping documentation requirements. The two skill sets rarely coexist in the same clinician, which means athletes often need a coordinated care arrangement.

Documentation for a TUE application should include: the clinical notes from at least two visits, all laboratory results with reference ranges and collection times, imaging reports if applicable, a clear diagnosis using ICD-10 coding (E29.1 for testicular hypofunction), evidence that non-prohibited treatments were tried or are medically unsuitable, and the proposed treatment protocol with dose, frequency, and monitoring plan.

The American Urological Association's 2018 guideline on testosterone deficiency, available through AUA's guidelines portal, states: "Clinicians should use a validated questionnaire to assess symptoms and monitor response to therapy." Using the ADAM questionnaire or the AMS scale and documenting baseline and follow-up scores adds objective support to a TUE application and to ongoing dose justification.

Athletes competing in Olympic or Paralympic pathways should contact their NADO's TUE department before any prescription is written. Getting testosterone therapy started and then applying for retroactive approval is a high-risk strategy with a low probability of success.